Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05422690 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 30, 2026 to Mar 30, 2027v12
  2. Re-verified, no change to tracked fieldsv11
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 15, 2024 to Jun 12, 2024
    • Site details revised
    v10
  4. Re-verified, no change to tracked fieldsv9
  5. Start date: Jan 30, 2024 to May 15, 2024v8 Show 4 more changesShow less
    • Eligibility criteria expanded, about 211 words
    • Site contact updated
    • Publications: 26 to 25
    • Study title revised
Show 6 earlier versionsHide 6 earlier versions
  1. Start date: Sep 30, 2023 to Jan 30, 2024v7
  2. Start date: Jun 1, 2023 to Sep 30, 2023
    • Primary completion date: Jul 31, 2026 to Sep 30, 2026
    • Study completion date: Jul 31, 2028 to Sep 30, 2028
    v6
  3. Start date: Feb 1, 2023 to Jun 1, 2023v5
  4. Start date: Nov 2022 to Feb 1, 2023v4
  5. Start date: Oct 2022 to Nov 2022
    • Study site revised
    v3
  6. Start date: Jul 1, 2022 to Oct 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this research is to see if combining gemcitabine, cisplatin and Durvalumab chemotherapy treatments with a direct tumor therapy called Yittrium-90, will work better together to shrink the tumor and control cancer.
Trial Details
NCT Number NCT05422690
Lead Sponsor Inova Health Care Services
Conditions
(from sponsor)		 Intrahepatic Cholangiocarcinoma
Related terms Cholangiocarcinoma
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov